MOTS vs. NMRD, VIVE, BRSH, UTRS, DRTSW, ANZUW, ATAKW, BBLGW, BRSHW, and CTCXW
Should you be buying Motus GI stock or one of its competitors? The main competitors of Motus GI include Nemaura Medical (NMRD), Viveve Medical (VIVE), Bruush Oral Care (BRSH), Minerva Surgical (UTRS), Alpha Tau Medical (DRTSW), Anzu Special Acquisition Corp I (ANZUW), Aurora Technology Acquisition (ATAKW), Bone Biologics (BBLGW), Bruush Oral Care (BRSHW), and Carmell (CTCXW). These companies are all part of the "medical equipment" industry.
Motus GI vs.
Nemaura Medical (NASDAQ:NMRD) and Motus GI (NASDAQ:MOTS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, community ranking, valuation, media sentiment, analyst recommendations, dividends and earnings.
4.4% of Nemaura Medical shares are owned by institutional investors. Comparatively, 20.1% of Motus GI shares are owned by institutional investors. 40.4% of Nemaura Medical shares are owned by company insiders. Comparatively, 0.3% of Motus GI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Motus GI received 159 more outperform votes than Nemaura Medical when rated by MarketBeat users. Likewise, 65.73% of users gave Motus GI an outperform vote while only 57.14% of users gave Nemaura Medical an outperform vote.
In the previous week, Nemaura Medical had 1 more articles in the media than Motus GI. MarketBeat recorded 1 mentions for Nemaura Medical and 0 mentions for Motus GI. Nemaura Medical's average media sentiment score of 0.00 equaled Motus GI'saverage media sentiment score.
Nemaura Medical has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Motus GI has higher revenue and earnings than Nemaura Medical. Motus GI is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Motus GI beats Nemaura Medical on 6 of the 9 factors compared between the two stocks.
Get Motus GI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Motus GI Competitors List
Related Companies and Tools
This page (NASDAQ:MOTS) was last updated on 1/21/2025 by MarketBeat.com Staff
